The STEAP4 target NQO1 mediates colon tumorigenesis

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Colorectal cancer (CRC) is a significant global health issue requiring novel therapeutic approaches.
• Six-transmembrane epithelial antigen of prostate 4 (STEAP4) has been implicated in colon tumorigenesis via reactive oxygen species (ROS) generation.
• Understanding STEAP4's role is critical for developing targeted CRC treatments.

Purpose of the Study:

• To investigate the functional role of STEAP4 in colon tumorigenesis.
• To elucidate the molecular mechanisms by which STEAP4 influences tumor growth.
• To evaluate STEAP4 as a potential therapeutic target for colorectal cancer.

Main Methods:

• Utilized a genetically engineered mouse model with STEAP4 knockout.
• Employed knockdown techniques to suppress STEAP4 expression.
• Analyzed the impact on the nuclear factor erythroid 2-related factor 2 (NRF2)-NAD(P)H:quinone oxidoreductase 1 (NQO1) signaling pathway.
• Assessed effects on apoptosis, autophagy, and xenograft tumor growth.
• Investigated STEAP4 overexpression effects and ferric iron dependency.
• Tested bioactivatable drugs targeting NQO1.

Main Results:

• STEAP4 knockout significantly reduced colon tumorigenesis in mice.
• STEAP4 suppression attenuated the NRF2-NQO1 pathway, inducing apoptosis and autophagy, and reducing tumor growth.
• STEAP4 overexpression increased ROS production and activated the NRF2-NQO1 pathway in a ferric iron-dependent manner.
• NQO1-targeting drugs effectively eradicated STEAP4-overexpressing colon cancer cells.

Conclusions:

• STEAP4 plays a critical role in promoting colon tumorigenesis.
• Modulating STEAP4 offers a promising therapeutic strategy for colorectal cancer.
• Targeting the NRF2-NQO1 pathway in conjunction with STEAP4 status presents a viable approach for CRC treatment.